Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Hard-to-Treat ovarian cancer

NCT ID NCT05041257

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a drug called mirvetuximab soravtansine in 79 people with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube cancers that have high levels of a protein called folate receptor-alpha. The drug is given by IV every three weeks. The main goal was to see how many participants' tumors shrank or disappeared. This study aims to offer a new treatment option for those whose cancer has returned after initial therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mirvetuximab soravtansine (a drug that targets cancer cells with high folate receptor-alpha)
What this could lead to
If successful, this could provide a new treatment option for people with recurrent ovarian cancer that still responds to platinum therapy.
What could go wrong
This is a small, single-arm phase 2 study without a comparison group, so results may not confirm effectiveness. Side effects from the drug could also limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm neoplasm ovarian cancer ovarian serous adenocarcinoma peritoneum cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CANCER PERITONEAL CANCER

Contacts and locations

Locations

  • Bon Secours Cork Hospital /ID# 269851

    Cork, T12 DV56, Ireland

  • Centre Armoricain de Radiotherapie Imagerie & Oncologie (CARIO) /ID# 269847

    Plérin, Cotes-d Armor, 22190, France

  • Centre Leon Berard /ID# 269848

    Lyon, Rhone, 69373, France

  • City of Hope National Medical Center /ID# 269928

    Duarte, California, 91010, United States

  • Cleveland Clinic Main Campus /ID# 269922

    Cleveland, Ohio, 44195, United States

  • Duplicate_SCRI - Tennessee Oncology /ID# 269921

    Nashville, Tennessee, 37203-1632, United States

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 269861

    Rome, Roma, 00168, Italy

  • Holy Name Medical Center /ID# 269927

    Teaneck, New Jersey, 07666, United States

  • Hospital Clínico Universitario de Valencia /ID# 269893

    Valencia, 46010, Spain

  • Hospital MD Anderson Cancer Center Madrid /ID# 269888

    Madrid, 28033, Spain

  • Hospital Universitario HM Sanchinarro /ID# 269891

    Madrid, 28050, Spain

  • Hospital Universitario La Paz /ID# 269890

    Madrid, 28046, Spain

  • Hospital Universitario Reina Sofia /ID# 269892

    Córdoba, Cordoba, 14004, Spain

  • Hospital Universitario Vall d'Hebron /ID# 269889

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen del Rocio /ID# 269894

    Seville, 41013, Spain

  • Hospital Universitario de Jaén /ID# 269895

    Jaén, Jaen, 23007, Spain

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 269862

    Bologna, 40138, Italy

  • Institut de Cancérologie de l'Ouest René Gauducheau /ID# 269846

    Saint-Herblain, Loire-Atlantique, 44805, France

  • Institut de cancérologie Strasbourg Europe (ICANS) /ID# 269849

    Strasbourg, 67200, France

  • Istituto Europeo Di Oncologia /ID# 269860

    Milan, Milano, 20141, Italy

  • Istituto Nazionale Dei Tumori /ID# 269864

    Milan, Milano, 20133, Italy

  • Istituto Nazionale Tumori Irccs Fondazione G. Pascale /ID# 269863

    Naples, Napoli, 80131, Italy

  • Monash Health - Monash Medical Centre /ID# 269735

    Clayton, Victoria, 3168, Australia

  • Newcastle Private Hosptial /ID# 269734

    Lambton Heights, New South Wales, 2305, Australia

  • Texas Oncology - South Austin /ID# 269924

    Austin, Texas, 78745, United States

  • The Mark H Zangmeister Center /ID# 269929

    Columbus, Ohio, 43219, United States

  • UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 269738

    Namur, 5000, Belgium

  • UZ Gent /ID# 269737

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Universitair Ziekenhuis Leuven /ID# 269736

    Leuven, Vlaams-Brabant, 3000, Belgium

  • University Colorado Cancer Center /ID# 269930

    Aurora, Colorado, 80045-2517, United States

  • University of California Los Angeles /ID# 269969

    Los Angeles, California, 90095-3075, United States

  • Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 269926

    Norfolk, Virginia, 23502, United States

  • Waterford Regional Hospital /ID# 269852

    Waterford, X91 ER8E, Ireland

  • Women & Infants Hospital /ID# 269923

    Providence, Rhode Island, 02905, United States

  • Women'S Cancer Care /ID# 269925

    Covington, Louisiana, 70433, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.